Flexion Therapeutics Stock Shares Owned By Institutions
Flexion Therapeutics fundamentals help investors to digest information that contributes to Flexion Therapeutics' financial success or failures. It also enables traders to predict the movement of Flexion Stock. The fundamental analysis module provides a way to measure Flexion Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Flexion Therapeutics stock.
Flexion |
Flexion Therapeutics Company Shares Owned By Institutions Analysis
Flexion Therapeutics' Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Current Flexion Therapeutics Shares Owned By Institutions | 92.20 % |
Most of Flexion Therapeutics' fundamental indicators, such as Shares Owned By Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Flexion Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
CompetitionBased on the latest financial disclosure, 92% of Flexion Therapeutics are shares owned by institutions. This is 106.54% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The shares owned by institutions for all United States stocks is 135.14% lower than that of the firm.
Flexion Shares Owned By Institutions Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Flexion Therapeutics' direct or indirect competition against its Shares Owned By Institutions to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Flexion Therapeutics could also be used in its relative valuation, which is a method of valuing Flexion Therapeutics by comparing valuation metrics of similar companies.Flexion Therapeutics is currently under evaluation in shares owned by institutions category among related companies.
Flexion Fundamentals
| Return On Asset | -18.99 | |||
| Profit Margin | (92.52) % | |||
| Operating Margin | (71.24) % | |||
| Current Valuation | 408.79 M | |||
| Shares Outstanding | 49.94 M | |||
| Shares Owned By Insiders | 3.58 % | |||
| Shares Owned By Institutions | 92.20 % | |||
| Number Of Shares Shorted | 5.67 M | |||
| Price To Earning | (8.29) X | |||
| Price To Book | 35.88 X | |||
| Price To Sales | 4.43 X | |||
| Revenue | 102.74 M | |||
| Gross Profit | 66.53 M | |||
| EBITDA | (71.2 M) | |||
| Net Income | (95.05 M) | |||
| Cash And Equivalents | 131.43 M | |||
| Cash Per Share | 2.61 X | |||
| Total Debt | 228.9 M | |||
| Current Ratio | 4.61 X | |||
| Book Value Per Share | (0.78) X | |||
| Cash Flow From Operations | (59.19 M) | |||
| Short Ratio | 3.74 X | |||
| Earnings Per Share | (2.20) X | |||
| Price To Earnings To Growth | (0.19) X | |||
| Number Of Employees | 257 | |||
| Beta | 1.34 | |||
| Market Capitalization | 455.47 M | |||
| Total Asset | 127.14 M | |||
| Retained Earnings | (686.19 M) | |||
| Working Capital | 104.04 M | |||
| Current Asset | 112.1 M | |||
| Current Liabilities | 8.06 M | |||
| Z Score | -6.4 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Other Consideration for investing in Flexion Stock
If you are still planning to invest in Flexion Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Flexion Therapeutics' history and understand the potential risks before investing.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |